Moderna (MRNA) Stock Looks Good With COVID-19 Studies Starting Today

Moderna MRNA Stock News

Moderna Inc (NASDAQ: MRNA) is seeing modest gains this morning, trading up more than 3%. While the company hasn’t issued any news this morning, there’s good reason for the gains and the stock could move higher ahead. It all has to do with the company’s work to develop a coronavirus vaccine and a statement made by a government official.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

MRNA Stock Up As Coronavirus Vaccine Enters Studies

According to a statement made by a government official, a clinical trial evaluating a coronavirus vaccine will start today. The first participant in the trial will receive the experimental vaccine today.

While the government official made the statement, they did not provide any company’s name as the trial has not yet been publicly announced. Nonetheless, the study will take place at the Kaiser Permanente Washington Health Research Institute in Seattle.

So why is Moderna flying. Well, because it is the company behind the clinical trials that begin today. The testing will start with 45 young, healthy volunteers, who will be provided a range of doses of the vaccine developed by NIH and MRNA.

Public health officials say it will take a year to 18 months to fully validate any potential vaccine. The goal of this first phase of testing is to show that the potential vaccine comes with no concerning adverse events. If all goes well, larger tests will begin shortly after the close of the Phase 1.

While any viable vaccine will take 18 months to produce, today, MRNA is taking the lead in a big way as it is the first to not only announce clinical trials, but does patients in these trials in the assessment of a COVID-19 vaccine.

This Is Big News

The novel coronavirus is no laughin matter. Well over 100,000 people around the world have already been infected, the death toll has risen to over 7,000 and the United States seems to be shutting down as a result.

As the virus continues to spread, the urgent need for a vaccine is only growing, and Moderna is leading the charge in bringing one to market. Of course, no one knows just how trials will go, but if all goes well, MRNA could be the first to bring a vaccine for COVID-19 to market.

Of course, the first company to produce a viable coronavirus vaccine will be sitting on a figurative goldmine. After all, demand for a vaccine is only growing, and speed is key. So, the first will likely quickly become the leader in the space, and MRNA has a good chance of being this player.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.